Product news from 09/09 News Brief

Share this article:

Takeda Pharmaceuticals North America announced that the FDA has approved the New Drug Application for ACTOplus Met for the treatment of type 2 diabetes.

Cephalon has entered into an agreement with McNeil Consumer & Specialty Pharmaceuticals to co-promote Attenace (modafinil) Tablets. Attenace is Cephalon's proprietary dosage form of modafinil, which is awaiting FDA approval for the treatment of attention-deficit/hyperactivity disorder (ADHD) in children and adolescents. 

Share this article:

Email Newsletters

More in News

Astellas, DOJ settle for $7.3M

Astellas, DOJ settle for $7.3M

Astellas has settled a False Claims case with the Department of Justice over the 2010-2013 marketing of an antifungal medication. Astellas denies the allegations.

Boehringer drug lands US, EU orphan tag

Boehringer drug lands US, EU orphan tag

The experimental Breakthrough Therapy treatment is for acute myeloid leukemia.

Omnio app moves to smartphones

Omnio app moves to smartphones

Physicians Interactive is introducing the third wave of its Omnio app, making the tablet-only tool available for iPhones and Android phones.